Christine Zedelmayer Sells 120,312 Shares of Equillium (NASDAQ:EQ) Stock

Equillium, Inc. (NASDAQ:EQ) COO Christine Zedelmayer sold 120,312 shares of the stock in a transaction on Friday, March 13th. The shares were sold at an average price of $2.50, for a total value of $300,780.00. Following the sale, the chief operating officer directly owned 62,586 shares in the company, valued at $156,465. This trade represents a 65.78% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Christine Zedelmayer also recently made the following trade(s):

• On Monday, March 9th, Christine Zedelmayer sold 181,219 shares of Equillium stock. The stock was sold at an average price of $2.00, for a total value of $362,438.00.
• On Thursday, February 19th, Christine Zedelmayer sold 185,937 shares of Equillium stock. The stock was sold at an average price of $1.76, for a total value of $327,249.12.
• On Tuesday, December 23rd, Christine Zedelmayer sold 100,000 shares of Equillium stock. The shares were sold at an average price of $1.50, for a total value of $150,000.00.

Equillium Price Performance

EQ opened at $2.15 on Wednesday. The business’s 50-day moving average is $1.57 and its two-hundred day moving average is $1.42. Equillium, Inc. has a 1 year low of $0.27 and a 1 year high of $2.70. The firm has a market capitalization of $130.92 million, a PE ratio of -3.47 and a beta of 1.80.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on EQ. Wall Street Zen raised shares of Equillium from a “sell” rating to a “hold” rating in a research report on Saturday. Zacks Research upgraded shares of Equillium to a “hold” rating in a research note on Thursday, February 26th. Roth Mkm began coverage on shares of Equillium in a report on Friday, March 13th. They issued a “buy” rating and a $12.00 price target on the stock. Stifel Nicolaus assumed coverage on Equillium in a research report on Wednesday, February 25th. They set a “buy” rating and a $5.00 price target on the stock. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Equillium in a report on Monday, December 29th. Two analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Equillium has an average rating of “Hold” and a consensus price target of $6.00.

Institutional Investors Weigh In On Equillium

A number of large investors have recently modified their holdings of the business. Cantor Fitzgerald L. P. purchased a new position in shares of Equillium in the 3rd quarter valued at approximately $608,000. Aberdeen Group plc acquired a new stake in Equillium in the 3rd quarter worth approximately $543,000. Virtu Financial LLC grew its position in Equillium by 133.4% during the 3rd quarter. Virtu Financial LLC now owns 23,779 shares of the company’s stock worth $34,000 after purchasing an additional 13,591 shares during the last quarter. Royal Bank of Canada acquired a new position in Equillium during the 4th quarter valued at approximately $124,000. Finally, Boothbay Fund Management LLC acquired a new position in Equillium during the 3rd quarter valued at approximately $174,000. Hedge funds and other institutional investors own 27.05% of the company’s stock.

Equillium Company Profile

Equillium, Inc (NASDAQ: EQ) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies to treat severe autoimmune diseases and prevent organ transplant rejection. The company’s lead therapeutic candidate, EQ001 (itolizumab), is a humanized monoclonal antibody that modulates T-cell activation by targeting the CD6 receptor. Equillium’s pipeline also includes additional biologic candidates aimed at addressing indications such as acute graft-versus-host disease (GVHD) and lupus nephritis.

Founded in 2015 and headquartered in La Jolla, California, Equillium in-licensed itolizumab from Biocon Limited, leveraging the antibody’s established safety profile in earlier clinical studies.